Preliminary results of a phase 1/2, first-in-human, open-label, dose escalation study of ZL-1211 (anti-Claudin 18.2 mAb) in patients with unresectable or metastatic solid tumors

被引：0
|
作者：
Sharma, Sunil
Starodub, Alexander
Xu, Nong
Chaudhry, Arvind
Sun, Meili
Pelster, Meredith
Fu, Yinjia
Zhang, Xinyu
Huang, Zhao
Liu, Wenyu
Hsu, Karl
机构：
[1] Honor Hlth, Scottsdale, AZ USA
[2] Parkview Canc Inst, Parkview Physician Grp, Cincinnati, OH USA
[3] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China
[4] Summit Canc Centers, Spokane Valley, WA USA
[5] Jinan Cent Hosp, Jinan, Peoples R China
[6] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
[7] Zai Lab Shanghai Co Ltd, Shanghai, Peoples R China
[8] Zai Lab Shanghai Co Ltd, R&D Dept, Shanghai, Peoples R China
[9] Zai Lab US LLC, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2537
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors
    Minami, Hironobu
    Ando, Yuichi
    Ma, Brigette Buig Yue
    Lee, Jih-Hsiang
    Momota, Hiroyuki
    Fujiwara, Yutaka
    Li, Leung
    Fukino, Koichi
    Ito, Koji
    Tajima, Takeshi
    Mori, Asuka
    Lin, Chia-Chi
    CANCER SCIENCE, 2016, 107 (10) : 1477 - 1483
  • [42] A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC410 in subjects with advanced or metastatic solid tumors.
    Gutierrez, Martin
    Janku, Filip
    Tian, Linjie
    Luke, Jason J.
    Shum, Elaine
    Shin, John
    Weiss, Ido
    Liu, Linda N.
    Files, Dallas
    Langermann, Solomon
    Myint, Han
    Bilusic, Marijo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] Phase I/II open-label study on an anti-GPC3 T cell engager, SAR444200, in patients with advanced solid tumors: Preliminary dose escalation results
    Hong, J. Yong
    Ryoo, B-Y.
    Chenard-Poirier, M.
    Almhanna, K.
    Lim, D. W. T.
    Samol, J.
    Abbadessa, G.
    Meng, R.
    Masciari, S.
    Kefsi, A.
    Zhang, Y.
    Guillemin-Paveau, H.
    Pasquier, B.
    Lepine, L.
    Dumbrava, E. E.
    ANNALS OF ONCOLOGY, 2023, 34 : S634 - S634
  • [44] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Andrea Wang-Gillam
    William Schelman
    Stacey Ukrainskyj
    Caly Chien
    Martha Gonzalez
    Zhao Yang
    Marek Kania
    Heather Yeckes-Rodin
    Investigational New Drugs, 2023, 41 (6) : 851 - 860
  • [45] A phase 1 B, open-label, dose-escalation study of bortezomib (Btz) in combination with gemcitabine (G) and cisplatin (C) in the first-line treatment of patients with advanced solid tumors: preliminary results
    Voortman, J.
    Smit, E. F.
    Kuenen, B. C.
    van de Velde, H.
    Giaccone, G.
    EJC SUPPLEMENTS, 2005, 3 (02): : 425 - 425
  • [46] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Wang-Gillam, Andrea
    Schelman, William
    Ukrainskyj, Stacey
    Chien, Caly
    Gonzalez, Martha
    Yang, Zhao
    Kania, Marek
    Yeckes-Rodin, Heather
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (06) : 851 - 860
  • [47] A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors
    Naing, Aung
    Gainor, Justin F.
    Gelderblom, Hans
    Forde, Patrick M.
    Butler, Marcus O.
    Lin, Chia-Chi
    Sharma, Sunil
    de Olza, Maria Ochoa
    Varga, Andrea
    Taylor, Matthew
    Schellens, Jan H. M.
    Wu, Hongqian
    Sun, Haiying
    Silva, Antonio P.
    Faris, Jason
    Mataraza, Jennifer
    Cameron, Scott
    Bauer, Todd M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [48] A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb), in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors
    Ganju, Vinod
    Cooper, Adam
    Gao, Bo
    Wilkinson, Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors
    Davis, Elizabeth J.
    Martin-Liberal, Juan
    Kristeleit, Rebecca
    Cho, Daniel C.
    Blagden, Sarah P.
    Berthold, Dominik
    Cardin, Dana B.
    Vieito, Maria
    Miller, Rowan E.
    Dass, Prashanth Hari
    Orcurto, Angela
    Spencer, Kristen
    Janik, John E.
    Clark, Jason
    Condamine, Thomas
    Pulini, Jennifer
    Chen, Xuejun
    Mehnert, Janice M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (10)
  • [50] A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors
    Duca, Matteo
    Lim, Darren Wan-Teck
    Subbiah, Vivek
    Takahashi, Shunji
    Sarantopoulos, John
    Varga, Andrea
    D'Alessio, Joseph A.
    Abrams, Tinya
    Sheng, Qing
    Tan, Eugene Youchin
    Rosa, Maria Santos
    Gonzalez-Maffe, Juan
    Sand-Dejmek, Janna
    Fabre, Claire
    Martin, Miguel
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (04) : 625 - 634
12345